China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd has received marketing approval from the National Medical Products Administration (NMPA) for its tulobuterol patch. This marks the first approval of its kind domestically in China for a transdermal patch designed to relieve respiratory distress caused by airway obstructive diseases.
Innovative Transdermal Delivery System
The tulobuterol patch achieves sustained drug release through a transdermal delivery system. It is designed to continuously dilate the bronchi during high-risk periods, such as the “morning descent,” thereby reducing the risk of nighttime onset. The patch is approved for use in relieving symptoms associated with airway obstructive diseases, including bronchial asthma, acute bronchitis, chronic bronchitis, and emphysema.
Future Development and Market Potential
With this approval, Sino Biopharmaceutical is poised to expand its presence in the respiratory health market. The innovative delivery system of the tulobuterol patch offers a convenient and effective treatment option for patients suffering from respiratory distress, positioning the company for further growth in this therapeutic area.-Fineline Info & Tech
